<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692207</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0684</org_study_id>
    <nct_id>NCT04692207</nct_id>
  </id_info>
  <brief_title>Prostate Biopsies With Target Lesion on MRI</brief_title>
  <official_title>Prostate Biopsies With Target Lesion on MRI : When Can Non-targeted Biopsies be Dispensed With</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective is to search for clinical, biological and imaging element that would better&#xD;
      define the patient population that could benefit from targeted prostate biopsies only (from a&#xD;
      cohort of patients who had targeted and non-targeted prostate biopsies).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Non-targeted biopsy not finding cancer of finding cancer of a grade lower than or egal to that found on targeted biopsies</measure>
    <time_frame>1 month</time_frame>
    <description>Non-targeted biopsy not finding cancer of finding cancer of a grade lower than or egal to that found on targeted biopsies</description>
  </primary_outcome>
  <enrollment type="Actual">151</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had a prostate MRI between June 2017 and March 2020 for suspected cancer,&#xD;
        followed by targeted and non-targeted prostate biopsies (12) at the Montpellier University&#xD;
        Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age &gt; or = at 18 years old&#xD;
&#xD;
          -  Prostatic MRI performed at the Montpellier University Hospital&#xD;
&#xD;
          -  Realization of targeted prostate biopsies (by fusion of MRI - ultrasound images) and&#xD;
             non-targeted biopsies&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pre-biopsy MRI performed outside of the Montpellier University Hospital&#xD;
&#xD;
          -  MRI with artefacts&#xD;
&#xD;
          -  Not performing 12 non-targeted prostate biopsies&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Millet, PUPH</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Targeted prostate biopsy</keyword>
  <keyword>Non-targeted prostate biopsy</keyword>
  <keyword>MRI</keyword>
  <keyword>prostate</keyword>
  <keyword>biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema Multiforme</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

